233 related articles for article (PubMed ID: 25194664)
1. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
[TBL] [Abstract][Full Text] [Related]
2. Intensity-modulated Radiation Therapy for Anal Cancer: Results From a Multi-Institutional Retrospective Cohort Study.
Call JA; Prendergast BM; Jensen LG; Ord CB; Goodman KA; Jacob R; Mell LK; Thomas CR; Jabbour SK; Miller RC
Am J Clin Oncol; 2016 Feb; 39(1):8-12. PubMed ID: 24401669
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of definitive radiation with volumetric modulated arc therapy and concurrent chemotherapy for squamous cell carcinoma of the anus in a regional Australian cancer centre.
Hsieh MT; Shakespeare TP; Winkley L; Goonetilleke D; Yap SZL; Tahir ARM
J Med Imaging Radiat Oncol; 2024 Apr; 68(3):325-332. PubMed ID: 38450897
[TBL] [Abstract][Full Text] [Related]
4. Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers.
Miah AB; Bhide SA; Guerrero-Urbano MT; Clark C; Bidmead AM; St Rose S; Barbachano Y; A'hern R; Tanay M; Hickey J; Nicol R; Newbold KL; Harrington KJ; Nutting CM
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):539-47. PubMed ID: 21236602
[TBL] [Abstract][Full Text] [Related]
5. High-tailored Anal Canal Radiotherapy (HIT-ART): Outcomes of a 10-Year Single Center Clinical Experience.
Manfrida S; Fionda B; Mariani S; Luca V; Bertolini R; Barbaro B; Chiloiro G; Frascino V; Tagliaferri L; Gambacorta MA
In Vivo; 2024; 38(3):1306-1315. PubMed ID: 38688632
[TBL] [Abstract][Full Text] [Related]
6. Patterns and Predictors of Relapse Following Radical Chemoradiation Therapy Delivered Using Intensity Modulated Radiation Therapy With a Simultaneous Integrated Boost in Anal Squamous Cell Carcinoma.
Shakir R; Adams R; Cooper R; Downing A; Geh I; Gilbert D; Jacobs C; Jones C; Lorimer C; Namelo WC; Sebag-Montefiore D; Shaw P; Muirhead R
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):329-339. PubMed ID: 31629837
[TBL] [Abstract][Full Text] [Related]
7. Quality of Life Longitudinal Evaluation in Prostate Cancer Patients from Radiotherapy Start to 5 Years after IMRT-IGRT.
Maggio A; Rancati T; Gatti M; Cante D; Avuzzi B; Bianconi C; Badenchini F; Farina B; Ferrari P; Giandini T; Girelli G; Landoni V; Magli A; Moretti E; Petrucci E; Salmoiraghi P; Sanguineti G; Villa E; Waskiewicz JM; Guarneri A; Valdagni R; Fiorino C; Cozzarini C
Curr Oncol; 2024 Feb; 31(2):839-848. PubMed ID: 38392056
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of the lymph node ratio for local advanced gastric cancer patients with intensity-modulated radiation therapy and concurrent chemotherapy after radical gastrectomy in China.
Yang Y; Ma Y; Xiang X; Xing P; Wu Y; Zhang L; Tian Y
Radiat Oncol; 2020 Oct; 15(1):237. PubMed ID: 33054848
[TBL] [Abstract][Full Text] [Related]
9. Toxicities and clinical outcome of adjuvant dysphagia optimized versus standard intensity-modulated radiotherapy for post-operative oral cavity cancers: A prospective comparative study.
Patni A; Rastogi M; Gandhi AK; Mishra VK; Srivastava AK; Sharma V; Agarwal A; Khurana R; Hadi R; Sapru S; Mishra SP
Head Neck; 2023 Dec; 45(12):3119-3128. PubMed ID: 37814926
[TBL] [Abstract][Full Text] [Related]
10. Feasibility Trial of Intensity Modulated Proton Therapy to Reduce Toxicity in Anal Cancer Patients.
Nelson B; Meier T; Zhang Y; Wang K; Mascia AE; Paquette I; Thompson E; Rafferty J; Snyder J; Olowokure O; Sohal D; Kharofa J
Am J Clin Oncol; 2023 Jul; 46(7):293-299. PubMed ID: 37088904
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric rationale and preliminary experience in proton plus carbon-ion radiotherapy for esophageal carcinoma: a retrospective analysis.
Ma N; Ming X; Chen J; Wu KL; Lu J; Jiang G; Mao J
Radiat Oncol; 2023 Dec; 18(1):195. PubMed ID: 38041122
[TBL] [Abstract][Full Text] [Related]
12. Prospective randomised phase II trial evaluating adjuvant pelvic radiotherapy using either IMRT or 3-Dimensional planning for endometrial cancer.
Nugent K; Browne D; Dunne M; O Sullivan L; Shannon AM; Sharma D; Bradshaw S; McArdle O; Salib O; Lavan N; Gillham C
Acta Oncol; 2023 Aug; 62(8):907-914. PubMed ID: 37493622
[TBL] [Abstract][Full Text] [Related]
13. Concurrent Chemo-radiotherapy in Anal Squamous Cell Carcinoma: A Retrospective Review of a Tertiary Centre Experience.
Patel C; Elmasry A; Giridharan S
J Gastrointest Cancer; 2023 Sep; 54(3):867-872. PubMed ID: 36269537
[TBL] [Abstract][Full Text] [Related]
14. ROAR-A: re-optimization based Online Adaptive Radiotherapy of anal cancer, a prospective phase II trial protocol.
Storm KS; Åström LM; Sibolt P; Behrens CP; Persson GF; Serup-Hansen E
BMC Cancer; 2024 Mar; 24(1):374. PubMed ID: 38528456
[TBL] [Abstract][Full Text] [Related]
15. Executive Summary of the American Radium Society Appropriate Use Criteria for Treatment of Anal Cancer.
Russo S; Anker CJ; Abdel-Wahab M; Azad N; Bianchi N; Das P; Dragovic J; Goodman KA; Jones W; Kennedy T; Kumar R; Lee P; Sharma N; Small W; Suh WW; Jabbour SK
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):591-605. PubMed ID: 31288054
[No Abstract] [Full Text] [Related]
16. Impact of radiation dose on patient-reported acute taste alteration in a prospective observational study cohort in head and neck squamous cell cancer (HNSCC).
Morelli I; Desideri I; Romei A; Scoccimarro E; Caini S; Salvestrini V; Becherini C; Livi L; Bonomo P
Radiol Med; 2023 Dec; 128(12):1571-1579. PubMed ID: 37642816
[TBL] [Abstract][Full Text] [Related]
17. Acute and Chronic Complications After Treatment of Locoregional Anal Cancer: Prevention and Management Strategies.
Katz L; Horowitz DP; Kachnic LA
J Natl Compr Canc Netw; 2023 Nov; 21(11):1204-1211. PubMed ID: 37935101
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of toxicity in patients with anal cancer undergoing definitive simultaneous integrated boost (SIB) or sequential integrated boost (SeqB) radiotherapy.
Rotondi M; Facondo G; Mossa S; Vullo G; Angelicone I; Valeriani M; Osti MF
Int J Colorectal Dis; 2023 May; 38(1):125. PubMed ID: 37171509
[TBL] [Abstract][Full Text] [Related]
19. Postoperative Hypofractionated Intensity-Modulated Radiotherapy With Concurrent Chemotherapy in Cervical Cancer: The POHIM-CCRT Nonrandomized Controlled Trial.
Cho WK; Park W; Kim SW; Lee KK; Ahn KJ; Choi JH
JAMA Oncol; 2024 Apr; ():. PubMed ID: 38662364
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC).
Fish R; Sanders C; Ryan N; der Veer SV; Renehan AG; Williamson PR
Colorectal Dis; 2018 May; 20(5):371-382. PubMed ID: 29566456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
